Effects of Leuzea carthamoides on Human Breast Adenocarcinoma MCF-7 Cells Determined by Gene Expression Profiling and Functional Assays

Abstract

Products derived from roots of Leuzea carthamoides (Maral root) are being promoted as dietary supplements with anti-aging, adaptogenic and anabolic activity, without much scientific evidence. We investigated the effects of a lipophilic Leuzea root extract and the major phytoecdysteroid, 20-hydroxyecdysone, in human breast adenocarcinoma MCF-7 cells. Cell proliferation was inhibited by the extract (IC₅₀ = 30 μg/mL) but not by 20-hydroxyecdysone. Genome-wide expression profiling using Affymetrix HG U133 Plus 2.0 microarrays was carried out to analyse effects at the transcriptional level. 241 genes appeared to be differentially expressed after Leuzea treatment, more than after treatment with either 17β-estradiol or tamoxifen. Transcripts linked to cell cycle regulation and DNA replication were highly over-represented and regulated in an anti-proliferative manner. Genes involved in apoptosis were regulated in a pro-apoptotic manner. Expression levels of several oxidoreductase transcripts were strongly induced, most prominent CYP1A1, known to be regulated via the aryl hydrocarbon receptor pathway. An XRE-dependent reporter gene assay confirmed the AhR-agonistic activity of the Leuzea root extract, whereas 20-hydroxyecdysone was not active. Leuzea extract also inhibited 5α-reductase, type II. While the extract significantly modulates cellular activities, the phytoecdysteroids, are most likely not the active principles of L. carthamoides.

Abbreviations

AhR:aryl hydrocarbon receptor

AKR:aldo-keto reductase

CYP1A1:cytochrome P450, family 1, subfamily A, polypeptide 1

E2:17β-estratiol

ER:estrogen receptor

20-HE:20-hydroxyecdysone

Key words

Leuzea carthamoides - Asteraceae - phytoecdysteroids - expression profiling - CYP1A1 - aryl hydrocarbon receptor

References

• 1 Varga E, Szendrei K, Hajdu Z, Hornok L, Csáki G. Study of the compounds contained in Hungarian-grown Leuzea carthamoides D.C., (Asteraceae), with special regard to ecdysteroids.  Herba Hung. 1986;  25 115-33
• 2 Szendrei K, Reisch J, Varga E. Thiophene acetylenes from Leuzea roots.  Phytochemistry. 1984;  23 901-2
• 3 Chobot V, Vytlacilova J, Kubicova L, Opletal L, Jahodar L, Laakso I. et al . Phototoxic activity of a thiophene polyacetylene from Leuzea carthamoides. .  Fitoterapia. 2006;  77 194-8
• 4 Pavlík M, Laudová V, Gruner K, Vokac K, Harmatha J. High-performance liquid chromatographic analysis and separation of N-feruloylserotonin isomers.  J Chromatogr B. 2002;  770 291-5
• 5 Grimshaw J, Jaruszelski M, Lamerzarawska E, Rzadkowska-Bodalska H. Sterols and new triterpenoid alcohol from Leuzea carthamoides (Willd.) DC.  Pol J Chem. 1981;  55 2355-8
• 6 Lafont R, Dinan L. Practical uses for ecdysteroids in mammals including humans: an update.  J Insect Sci. 2003;  3 7
• 7 Le Bizec B, Antignac J P, Monteau F, Andre F. Ecdysteroids: one potential new anabolic family in breeding animals.  Anal Chim Acta. 2002;  473 89-97
• 8 Sláma K, Lafont R. Insect hormones – ecdysteroids: their presence and actions in vertebrates.  Eur J Entomol. 1995;  92 355-77
• 9 Dinan L, Lafont R. Effects and applications of arthropod steroid hormones (ecdysteroids) in mammals.  J Endocrinol. 2006;  191 1-8
• 10 Vienonen A, Miettinen S, Manninen T, Altucci L, Wilhelm E, Ylikomi T. Regulation of nuclear receptor and cofactor expression in breast cancer cell lines.  Eur J Endocrinol. 2003;  148 469-79
• 11 Safe S, Wormke M, Samudio I. Mechanisms of inhibitory aryl hydrocarbon receptor-estrogen receptor crosstalk in human breast cancer cells.  J Mammary Gland Biol Neoplasia. 2000;  5 295-306
• 12 Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays.  J Immunol Methods. 1983;  65 55-63
• 13 Denizot F, Lang R. Rapid colorimetric assay for cellular growth and survival: Modifications to the tetrazolium dye procedure giving improved sensivity and reliability.  J Immunol Methods. 1986;  89 271-7
• 14 Kroll T C, Wolfl S. Ranking: a closer look on globalisation methods for normalisation of gene expression arrays.  Nucleic Acids Res. 2002;  30 e50
• 15 Bolstad B M, Irizarry R A, Astrand M, Speed T P. A comparison of normalization methods for high density oligonucleotide array data based on bias and variance.  Bioinformatics. 2003;  19 185-93
• 16 Irizarry R A, Bolstad B M, Collin F, Cope L M, Hobbs B, Speed T P. Summaries of Affymetrix GeneChip probe level data.  Nucleic Acids Res. 2003;  31 e15
• 17 Baumgart A, Schmidt M, Schmitz H J, Schrenk D. Natural furanocoumarins as inducers and inhibitors of cytochrome P450 1A1 in rat hepatocytes.  Biochem Pharmacol. 2005;  69 657-67
• 18 Reichert W, Hartmann R W, Jose J. Stable expression of the human 5alpha-reductase isoenzymes type I and type II in HEK293 cells to identify dual and selective inhibitors.  J Enzyme Inhib. 2001;  16 47-53
• 19 Panter B U, Jose J, Hartmann R W. 5alpha-Reductase in human embryonic kidney cell line HEK293: evidence for type II enzyme expression and activity.  Mol Cell Biochem. 2005;  270 201-8
• 20 Villalobos M, Olea N, Brotons J A, Olea-Serrano M F, Ruiz de Almodovar J M, Pedraza V. The E-screen assay: a comparison of different MCF7 cell stocks.  Environ Health Perspect. 1995;  103 844-50
• 21 Tian C Y, Hu C Q, Xu G, Song H Y. Assessment of estrogenic activity of natural compounds using improved E-screen assay.  Acta Pharmacol Sin. 2002;  23 572-6
• 22 Denison M S, Phelan D, Elferink C J. The Ah receptor signal transduction pathway. In: Denison MS, Helferich WG, editors. Toxicant-receptor-interactions.  Philadelphia: Taylor &. Francis;  1998 3-33
• 23 Ma Q, Baldwin K T, Renzelli A J, McDaniel A, Dong L. TCDD-inducible poly (ADP-ribose) polymerase: a novel response to 2,3,7,8-tetrachlorodibenzo-p-dioxin.  Biochem Biophys Res Commun. 2001;  289 499-506
• 24 Hanlon P R, Zheng W, Ko A Y, Jefcoate C R. Identification of novel TCDD-regulated genes by microarray analysis.  Toxicol Appl Pharmacol. 2005;  202 215-28.
• 25 Potterat O, Hamburger M. Natural products in drug discovery – concepts and approaches for tracking bioactivity.  Curr Org Chem. 2006;  10 899-920
• 26 Gaube F, Wolfl S, Pusch L, Kroll T C, Hamburger M. Gene expression profiling reveals effects of Cimicifuga racemosa (L.) NUTT. (black cohosh) on the estrogen receptor positive human breast cancer cell line MCF-7.  BMC Pharmacol. 2007;  7 11
• 27 Dalton T P, Puga A, Shertzer H G. Induction of cellular oxidative stress by aryl hydrocarbon receptor activation.  Chem Biol Interact. 2002;  141 77-95
• 28 Delescluse C, Lemaire G, de Sousa G, Rahmani R. Is CYP1A1 induction always related to AHR signaling pathway?.  Toxicology. 2001;  153 73-82
• 29 Parczyk K, Schneider M. The future of antihormone therapy: innovations based on anestablished principle.  J Cancer Res Clin Oncol. 1996;  122 383-96
• 30 Nawaz Z, Lonard D M, Dennis A P, Smith C L, O′Malley B W. Proteasome-dependent degradation of the human estrogen receptor.  Proc Natl Acad Sci USA. 1999;  96 1858-62
• 31 Wormke M, Stoner M, Saville B, Walker K, Abdelrahim M, Burghardt R. et al . The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes.  Mol Cell Biol. 2003;  23 1843-55
• 32 Ohtake F, Takeyama K, Matsumoto T, Kitagawa H, Yamamoto Y, Nohara K. et al . Modulation of oestrogen receptor signalling by association with the activated dioxin receptor.  Nature. 2003;  423 545-50
• 33 Wiebe J P, Muzia D, Hu J, Szwajcer D, Hill S A, Seachrist J L. The 4-pregnene and 5alpha-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion.  Cancer Res. 2000;  60 936-43
• 34 Wiebe J P. Progesterone metabolites in breast cancer.  Endocr Relat Cancer. 2006;  13 717-38
• 35 Wiebe J P, Lewis M J. Activity and expression of progesterone metabolizing 5alpha-reductase, 20alpha-hydroxysteroid oxidoreductase and 3alpha(beta)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47 D) and nontumorigenic (MCF-10A) human breast cancer cells.  BMC Cancer. 2003;  3 9
• 36 Lewis M J, Wiebe J P, Heathcote J G. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma.  BMC Cancer. 2004;  4 27
• 37 Pawlak K J, Wiebe J P. Regulation of estrogen receptor (ER) levels in MCF-7 cells by progesterone metabolites.  J Steroid Biochem Mol Biol. 2007;  107 172-9